| scholarly article | Q13442814 |
| P50 | author | Peter A. Newman | Q40025590 |
| P2093 | author name string | Naihua Duan | |
| Lisa Kakinami | |||
| Kathleen Roberts | |||
| P2860 | cites work | HIV-Related Stigma and Knowledge in the United States: Prevalence and Trends, 1991–1999 | Q22241451 |
| HIV vaccine trial preparedness among Spanish-speaking Latinos in the US. | Q30230248 | ||
| Listening to consumers and HIV vaccine preparedness | Q30233087 | ||
| Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation | Q30233275 | ||
| Posttrial HIV vaccine adoption: concerns, motivators, and intentions among persons at risk for HIV. | Q30343916 | ||
| HIV vaccine acceptability among communities at risk: the impact of vaccine characteristics | Q30352116 | ||
| HIV vaccine knowledge and beliefs among communities at elevated risk: conspiracies, questions and confusion. | Q30352418 | ||
| Forecasting the future of HIV epidemics: the impact of antiretroviral therapies & imperfect vaccines | Q34216467 | ||
| Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco | Q34332923 | ||
| Potential public health impact of imperfect HIV type 1 vaccines | Q34380779 | ||
| Challenges for HIV vaccine dissemination and clinical trial recruitment: if we build it, will they come? | Q36014102 | ||
| Estimation of ?needs? and ?probable uptake? for HIV/AIDS preventive vaccines based on possible policies and likely acceptance (a WHO/UNAIDS/IAVI study) | Q38883283 | ||
| HIV vaccine acceptability among women at risk: perceived barriers and facilitators to future HIV vaccine uptake | Q40406892 | ||
| HIV risk and prevention in a post-vaccine context | Q40513334 | ||
| Public health considerations for the use of a first generation HIV vaccine. Report from a WHO-UNAIDS-CDC consultation, Geneva, 20-21 November 2002 | Q40558622 | ||
| Who will enroll? Predicting participation in a phase II AIDS vaccine trial | Q40696143 | ||
| Attitudes about human immunodeficiency virus immunization: the influence of health beliefs and vaccine characteristics | Q45757194 | ||
| What can be achieved with an HIV vaccine? | Q46009424 | ||
| Participation in research and access to experimental treatments by HIV-infected patients | Q46500835 | ||
| HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment | Q46965041 | ||
| Calling the shots: immunization finance policies and practices. Executive summary of the report of the Institute of Medicine | Q50132476 | ||
| Community heroes or “high-risk” pariahs? Reasons for declining to enroll in an HIV vaccine trial | Q58452408 | ||
| Vaccine characteristics and acceptability of HIV immunization among adolescents | Q59559002 | ||
| Factors associated with the acceptance of an AIDS vaccine: an exploratory study | Q80534088 | ||
| Barriers to participating in an HIV vaccine trial: a systematic review | Q81091982 | ||
| Constructing Grounded Theory: A practical guide through qualitative analysis | Q88480597 | ||
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| HIV | Q15787 | ||
| P1104 | number of pages | 9 | |
| P304 | page(s) | 2528-2536 | |
| P577 | publication date | 2008-03-28 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | What can HIV vaccine trials teach us about future HIV vaccine dissemination? | |
| P478 | volume | 26 |
| Q38662018 | "Like Holding an Umbrella Before It Rains": Acceptability of Future Rectal Microbicides Among Men Who Have Sex With Men in India-A Modified Technology Acceptance Model |
| Q35219438 | "Once Bitten, Twice Shy": participant perspectives in the aftermath of an early HIV vaccine trial termination. |
| Q45205985 | "Once I begin to participate, people will run away from me": understanding stigma as a barrier to HIV vaccine research participation in Kenya |
| Q51692824 | "Speaking the dialect": understanding public discourse in the aftermath of an HIV vaccine trial shutdown. |
| Q58452343 | 'Why would you promote something that is less percent safer than a condom?': Perspectives on partially effective HIV prevention technologies among key populations in South Africa |
| Q58452373 | A social vaccine? Social and structural contexts of HIV vaccine acceptability among most-at-risk populations in Thailand |
| Q50135709 | Acceptability and Preferences for Hypothetical Rectal Microbicides among a Community Sample of Young Men Who Have Sex with Men and Transgender Women in Thailand: A Discrete Choice Experiment. |
| Q30226488 | Barriers of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies |
| Q59326978 | Clinical exigencies, psychosocial realities: negotiating HIV pre-exposure prophylaxis beyond the cascade among gay, bisexual and other men who have sex with men in Canada |
| Q27005602 | Combination HIV prevention interventions: the potential of integrated behavioral and biomedical approaches |
| Q35301155 | Conceptual framework for behavioral and social science in HIV vaccine clinical research |
| Q50114646 | Contexts of vulnerability and the acceptability of new biomedical HIV prevention technologies among key populations in South Africa: A qualitative study |
| Q45365760 | Does message framing predict willingness to participate in a hypothetical HIV vaccine trial: an application of Prospect Theory |
| Q30206105 | Effect of race/ethnicity on participation in HIV vaccine trials and comparison to other trials of biomedical prevention |
| Q35736408 | Engaging members of African American and Latino communities in preventive HIV vaccine trials |
| Q30227101 | Enhancing HIV vaccine trial consent preparedness among street drug users |
| Q39070305 | Factors influencing frontline health service providers' likelihood to recommend a future, preventive HIV vaccine to key populations in Karnataka, south India |
| Q33786360 | HIV vaccine acceptability among high-risk drug users in Appalachia: a cross-sectional study |
| Q52300855 | Immune to addiction: the ethical dimensions of vaccines against substance abuse. |
| Q44428535 | Integrating social and biomedical science in HIV vaccine research: obstacles, opportunities and ways forward |
| Q34123592 | Pre-exposure prophylaxis state of the science: empirical analogies for research and implementation |
| Q37386288 | Social and behavioral science in HIV vaccine trials: a gap assessment of the literature |
| Q30204342 | Socioeconomic status and HIV vaccine preparedness studies in North America |
| Q39405588 | The marginal willingness-to-pay for attributes of a hypothetical HIV vaccine. |
| Q41647548 | Typologies of Altruistic and Financial Motivations for Research Participation |
Search more.